Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Comparing haemophilus influenzae type b conjugate vaccine schedules: A systematic review and meta-analysis of vaccine trials
Pediatric Infectious Disease Journal, Volume 32, No. 11, Year 2013
Notification
URL copied to clipboard!
Description
BACKGROUND: The optimal schedule and the need for a booster dose are unclear for Haemophilus influenzae type b (Hib) conjugate vaccines. We systematically reviewed relative effects of Hib vaccine schedules. METHODS: We searched 21 databases to May 2010 or June 2012 and selected randomized controlled trials or quasi-randomized controlled trials that compared different Hib schedules (3 primary doses with no booster dose [3p+0], 3p+1 and 2p+1) or different intervals in primary schedules and between primary and booster schedules. Outcomes were clinical efficacy, nasopharyngeal carriage and immunological response. Results were combined in random-effects meta-analysis. RESULTS: Twenty trials from 15 countries were included; 16 used vaccines conjugated to tetanus toxoid (polyribosylribitol phosphate conjugated to tetanus toxoid). No trials assessed clinical or carriage outcomes. Twenty trials examined immunological outcomes and found few relevant differences. Comparing polyribosylribitol phosphate conjugated to tetanus toxoid 3p+0 with 2p+0, there was no difference in seropositivity at the 1.0 μg/mL threshold by 6 months after the last primary dose (combined risk difference -0.02; 95% confidence interval: -0.10, 0.06). Only small differences were seen between schedules starting at different ages, with different intervals between primary doses, or with different intervals between primary and booster doses. Individuals receiving a booster were more likely to be seropositive than those at the same age who did not. CONCLUSIONS: There is no clear evidence from trials that any 2p+1, 3p+0 or 3p+1 schedule of Hib conjugate vaccine is likely to provide better protection against Hib disease than other schedules. Until more data become available, scheduling is likely to be determined by epidemiological and programmatic considerations in individual settings. Copyright © 2013 by Lippincott Williams & Wilkins.
Authors & Co-Authors
Low, Nicola M.
Switzerland, Bern
University of Bern
Redmond, Shelagh M.S.
Switzerland, Bern
University of Bern
Rutjes, Anne W.S.
Switzerland, Bern
University of Bern
Italy, Chieti
University of G. D'annunzio Chieti and Pescara
Egger, Matthias
Switzerland, Bern
University of Bern
Di Nisio, Marcello
Italy, Chieti
University of G. D'annunzio Chieti and Pescara
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Scott, Pippa
Switzerland, Bern
University of Bern
Statistics
Citations: 16
Authors: 6
Affiliations: 4
Identifiers
Doi:
10.1097/INF.0b013e31829f0a7e
ISSN:
15320987
Study Approach
Systematic review